We can target the disparities in immune cell infiltration between colon cancer and normal intestinal tissue by developing targeted drugs that enhance the activity of specific immune cells, such as NK cells, CD8 T cells, etc., amplifying the activity and quantity of these immune cells and consequently eradicating cancer cells to achieve effective cancer treatment. The gene discussed is CD8A; the disease is cancer.